Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 290

Sort by

Sort Order Select

Journal Articles

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Jonathan L. Kaufman, Robert Z. Orlowski, Andras Strassz, Andreas Pahl, Thorsten Michaels, Anette Last, Hajnalka Szaboki, Garrit Jentsch, Oliver Schoenborn-Kellenberger, Marc-Steffen Raab

Blood (2022) 140 (Supplement 1): 7235–7236.

https://doi.org/10.1182/blood-2022-168848

Published: 2022

Journal Articles

Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

Oren Pasvolsky, Denái R Milton, Adeel Masood, Sophiya S Shehzad, Mark R Tanner, Qaiser Bashir, Samer A Srour, Neeraj Saini, Jeremy L. Ramdial, Yago Nieto, Hans C. Lee, Krina Patel, Partow Kebriaei, Sheeba K Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J Shpall, Richard E Champlin, Muzaffar H Qazilbash

Blood (2022) 140 (Supplement 1): 10589–10591.

https://doi.org/10.1182/blood-2022-162465

Published: 2022

Journal Articles

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Blood (2022) 140 (Supplement 1): 2232–2233.

https://doi.org/10.1182/blood-2022-160294

Published: 2022

Journal Articles

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Hans C. Lee, Gregory P. Kaufman, Lei Feng, Astrid Murga, Ralph J. Johnson, Donna M. Weber, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Swaminathan P. Iyer, Krina Patel, Melody R. Becnel, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4428–4430.

https://doi.org/10.1182/blood-2022-167555

Published: 2022

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Blood (2022) 140 (Supplement 1): 1146–1149.

https://doi.org/10.1182/blood-2022-162313

Published: 2022

Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Blood (2022) 140 (Supplement 1): 1142–1145.

https://doi.org/10.1182/blood-2022-165524

Published: 2022

Journal Articles

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Miguel Villareal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 9995–9997.

https://doi.org/10.1182/blood-2022-163092

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Blood (2022) 140 (Supplement 1): 10133–10136.

https://doi.org/10.1182/blood-2022-163555

Published: 2022

Journal Articles

Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma

Christopher J. Ferreri, Steven E. Quatela, Sean Aina, Pourab Roy, Anita Boyapati, Karen Rodriguez Lorenc, Glenn S. Kroog, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 10129–10130.

https://doi.org/10.1182/blood-2022-158396

Published: 2022

Journal Articles

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4349–4351.

https://doi.org/10.1182/blood-2022-166609

Published: 2022

Journal Articles

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Blood (2022) 140 (Supplement 1): 284–286.

https://doi.org/10.1182/blood-2022-157960

Published: 2022

Journal Articles

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Minghao Dang, Li Qin, Wei Tan, Liping Dong, Hans C. Lee, Krina Patel, Luz Yurany Moreno Rueda, Pei Lin, Hima Bansal, David Berrios, Sheeba K Thomas, Donna M. Weber, David E. Symer, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 7122–7124.

https://doi.org/10.1182/blood-2022-165540

Published: 2022

Journal Articles

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Paul G. Richardson, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z. Orlowski, Kihyun Kim, María-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Alessia Spirli, Ignacio Casas-Avilés, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Nizar J. Bahlis

Blood (2022) 140 (Supplement 1): 1366–1368.

https://doi.org/10.1182/blood-2022-157945

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 7297–7300.

https://doi.org/10.1182/blood-2022-163494

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Blood (2022) 140 (Supplement 1): 7278–7281.

https://doi.org/10.1182/blood-2022-162339

Published: 2022

Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2022) 140 (Supplement 1): 4834–4838.

https://doi.org/10.1182/blood-2022-162741

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 10150–10153.

https://doi.org/10.1182/blood-2022-163335

Published: 2022

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

Journal Articles

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Blood (2022) 139 (9): 1289–1301.

https://doi.org/10.1182/blood.2020008493

Published: 2022

Includes: Supplemental data

Journal Articles

M-Protein Sequencing and Monitoring in Serum of LC-Only Multiple Myeloma Patients

Mariya Liyasova, Natalia Migdal, Zac McDonald, Liqiang Yang, Bin Ma, Jesus Giovanni Piza, Donna E. Reece, Elisabet E. Manasanch, Robert Z. Orlowski, Suzanne Trudel, Gregory P. Kaufman

Blood (2021) 138 (Supplement 1): 4729.

https://doi.org/10.1182/blood-2021-149785

Published: 2021

NARROW

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

M-Protein Sequencing and Monitoring in Serum of LC-Only Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only